Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab extension study in Japanese patients with NMOSD
jRCT2051210017Active, not recruiting
- Sponsor
- Viela Bio
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) and neuromyelitis optica (NMO), sponsored by Viela Bio. Primary endpoints: Continuation of inebilizumab access, Long-term safety and laboratory effects and 1 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)neuromyelitis optica (NMO)
Beyond the preview
Go deeper on jRCT2051210017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210017.